Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
about
Available and emerging treatments for Parkinson's disease: a reviewThe recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's diseaseA systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Review: management of Parkinson's disease.Continuous drug delivery in Parkinson's disease.Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistPramipexole for the treatment of early Parkinson's disease.Monoamine reuptake inhibitors in Parkinson's disease.How to optimize the treatment of early stage Parkinson's disease.Dyskinesias and treatment with pramipexole in patients with Parkinson's disease.Clinical approach to Parkinson's disease: features, diagnosis, and principles of management.Clinical aspects and management of levodopa-induced dyskinesia.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsCD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease.Combination therapies: The next logical Step for the treatment of synucleinopathies?Caffeine consumption and risk of dyskinesia in CALM-PD.Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Current strategies in the treatment of Parkinson's disease and a personalized approach to management.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.Safinamide in the treatment of Parkinson's disease.Levodopa in the treatment of Parkinson's disease: an old drug still going strong.The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.Milestones in Parkinson's disease therapeutics.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Drug therapy in patients with Parkinson's disease.Management of motor and non-motor symptoms in Parkinson's disease.Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.Dopamine receptor agonists for Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Emerging drugs for levodopa-induced dyskinesia.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Levodopa alone compared with levodopa-sparing therapy as initial treatment for Parkinson's disease: a meta-analysis.
P2860
Q24633444-C8B9C5EB-BA9F-4109-8621-ED5242749B5FQ26745661-8210B263-56C2-49A7-8C42-0DBB25EF1392Q30240991-3B54D9D4-3B24-4C5C-BF19-A41A12430809Q33765388-E382AD3C-D4F5-49EB-AB54-8F886B2867FDQ34027880-2076FD41-C5F4-4331-B588-BBC240930E63Q34332812-1714A403-721B-4C7F-B4D7-61048142BAEEQ34390800-BA69733C-A6E8-43CD-87BD-551D4DE2C9D8Q34504316-5963F858-F701-4EFA-BB4E-74558CF951EFQ34630735-E902D394-3028-4DDA-8B9D-15BE3331F993Q35165280-1E9EDC5D-0709-4E6A-A622-921E90F748A7Q35599297-C0E46448-06D4-442E-AEF4-B58B60349339Q35837892-A74419DC-FA2D-4BEE-A89F-B55DAB6F7F24Q36009241-C57C487A-E1D5-4F5D-B5BA-FC77D6AE2F66Q36022700-D37B9299-B375-4794-92DD-CB68FC6B80E4Q36251899-21FD2C12-86D0-460C-B8B5-19FDC74264D2Q36449229-F611834D-88B1-4DC5-849F-E46B2E3C247FQ36563062-28677329-E94D-4F4C-9FD8-1D34788D8177Q36717838-3286AF64-B6D3-4127-927D-F3ED0A61CF33Q36941752-7E9346C8-4491-46B5-804E-8EA7EBBDF3EEQ37115650-4E322F80-36AA-4D21-A2C3-0A7262280D94Q37642000-E116DFEB-5C21-4E5D-AFF5-572B12A3848EQ37736512-60F91C59-2C55-415A-9B57-D59E57D1E273Q37776519-2BB411D5-CA1B-4710-81CF-943135D2DADDQ37779808-3E2F3F9E-5660-43E8-9477-1186ACF09744Q37790274-7A13BFA2-2585-4B0A-9E34-1DBE0C311613Q37841542-4E0DC526-2B75-411B-93DE-57129C9356B9Q37882596-1FA03BD0-6BB3-4036-9931-EAE3128B42DFQ37890986-A83C2B17-68ED-4189-A560-4BB2923DC59AQ37948713-C64055FC-F049-4F72-B77D-BFE464DC84A4Q37973462-648D97CE-B727-4722-92CF-BB58DC766AC1Q37979869-F92EE7CE-A281-4A58-BBAD-D32EBFED7702Q38064971-28AA9562-72BB-408A-BD65-C2B82E20BB10Q38091653-487EF3E1-108C-4015-8092-DB9A98A78C17Q38112219-036E3BE1-2C1A-46CF-8BBA-53E6CDC227FFQ38169202-AE39F712-495B-4F7C-AC7E-ED497E779738Q38178754-151A3AE3-8FB6-49E1-84D1-2121E95825DCQ38206403-D152EB87-54E6-4C63-B876-A977FD80B4E0Q38242091-3A6ABD33-E830-4921-AB55-DAE72F077109Q38314257-C117C057-E979-4E49-AD1B-6EFAEA77E2B2Q38485023-8A4713C1-3001-4166-921D-8A5DAA757033
P2860
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
@en
type
label
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
@en
prefLabel
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
@en
P1433
P1476
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
@en
P2093
Parkinson Study Group CALM Cohort Investigators
P304
P356
10.1001/ARCHNEUROL.2009.32
P577
2009-05-01T00:00:00Z